Telaprevir: Interim Phase IIb data

Interim data from the European Phase IIb PROVE 2 trial in treatment-naïve, genotype 1 HCV patients showed an SVR rate of 68% vs. 48% for placebo at 12 weeks post-treatment. The relapse rate in the tel...